Cargando…
P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428690/ http://dx.doi.org/10.1097/01.HS9.0000969416.78092.36 |
| _version_ | 1785090529273315328 |
|---|---|
| author | Woyach, Jennifer Flinn, Ian W. Awan, Farrukh Eradat, Herbert Brander, Danielle M. Tees, Michael Parikh, Sameer Phillips, Tycel Ghori, Razi Paydar, Ima Farooqui, Mohammed Z. H. Byrd, John C. Stephens, Deborah |
| author_facet | Woyach, Jennifer Flinn, Ian W. Awan, Farrukh Eradat, Herbert Brander, Danielle M. Tees, Michael Parikh, Sameer Phillips, Tycel Ghori, Razi Paydar, Ima Farooqui, Mohammed Z. H. Byrd, John C. Stephens, Deborah |
| author_sort | Woyach, Jennifer |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428690 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104286902023-08-17 P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES Woyach, Jennifer Flinn, Ian W. Awan, Farrukh Eradat, Herbert Brander, Danielle M. Tees, Michael Parikh, Sameer Phillips, Tycel Ghori, Razi Paydar, Ima Farooqui, Mohammed Z. H. Byrd, John C. Stephens, Deborah Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428690/ http://dx.doi.org/10.1097/01.HS9.0000969416.78092.36 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Woyach, Jennifer Flinn, Ian W. Awan, Farrukh Eradat, Herbert Brander, Danielle M. Tees, Michael Parikh, Sameer Phillips, Tycel Ghori, Razi Paydar, Ima Farooqui, Mohammed Z. H. Byrd, John C. Stephens, Deborah P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES |
| title | P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES |
| title_full | P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES |
| title_fullStr | P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES |
| title_full_unstemmed | P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES |
| title_short | P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES |
| title_sort | p628: updated analysis of bellwave-001: a phase 1/2 open-label dose-expansion study of the efficacy and safety of nemtabrutinib for the treatment of b-cell malignancies |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428690/ http://dx.doi.org/10.1097/01.HS9.0000969416.78092.36 |
| work_keys_str_mv | AT woyachjennifer p628updatedanalysisofbellwave001aphase12openlabeldoseexpansionstudyoftheefficacyandsafetyofnemtabrutinibforthetreatmentofbcellmalignancies AT flinnianw p628updatedanalysisofbellwave001aphase12openlabeldoseexpansionstudyoftheefficacyandsafetyofnemtabrutinibforthetreatmentofbcellmalignancies AT awanfarrukh p628updatedanalysisofbellwave001aphase12openlabeldoseexpansionstudyoftheefficacyandsafetyofnemtabrutinibforthetreatmentofbcellmalignancies AT eradatherbert p628updatedanalysisofbellwave001aphase12openlabeldoseexpansionstudyoftheefficacyandsafetyofnemtabrutinibforthetreatmentofbcellmalignancies AT branderdaniellem p628updatedanalysisofbellwave001aphase12openlabeldoseexpansionstudyoftheefficacyandsafetyofnemtabrutinibforthetreatmentofbcellmalignancies AT teesmichael p628updatedanalysisofbellwave001aphase12openlabeldoseexpansionstudyoftheefficacyandsafetyofnemtabrutinibforthetreatmentofbcellmalignancies AT parikhsameer p628updatedanalysisofbellwave001aphase12openlabeldoseexpansionstudyoftheefficacyandsafetyofnemtabrutinibforthetreatmentofbcellmalignancies AT phillipstycel p628updatedanalysisofbellwave001aphase12openlabeldoseexpansionstudyoftheefficacyandsafetyofnemtabrutinibforthetreatmentofbcellmalignancies AT ghorirazi p628updatedanalysisofbellwave001aphase12openlabeldoseexpansionstudyoftheefficacyandsafetyofnemtabrutinibforthetreatmentofbcellmalignancies AT paydarima p628updatedanalysisofbellwave001aphase12openlabeldoseexpansionstudyoftheefficacyandsafetyofnemtabrutinibforthetreatmentofbcellmalignancies AT farooquimohammedzh p628updatedanalysisofbellwave001aphase12openlabeldoseexpansionstudyoftheefficacyandsafetyofnemtabrutinibforthetreatmentofbcellmalignancies AT byrdjohnc p628updatedanalysisofbellwave001aphase12openlabeldoseexpansionstudyoftheefficacyandsafetyofnemtabrutinibforthetreatmentofbcellmalignancies AT stephensdeborah p628updatedanalysisofbellwave001aphase12openlabeldoseexpansionstudyoftheefficacyandsafetyofnemtabrutinibforthetreatmentofbcellmalignancies |